FDA Panel Narrowly Endorses AtriCure’s Synergy For A-Fib Ablation
This article was originally published in The Gray Sheet
Executive Summary
FDA’s Circulatory System Devices panel narrowly endorsed an expanded indication last week for AtriCure’s Synergy ablation system to treat certain types of atrial fibrillation during open-heart surgery, despite concerns over safety issues and limited data.
You may also be interested in...
New Products In Brief
AtriCure’s Synergy surgical ablation system for atrial fibrillation and J&J/DePuy’s next-generation polyethylene bearing for rotating platform and mobile bearing knees gain PMA approvals. More new products.
AF Ablation: Surgery And Catheter Techniques Both Shine At AHA
Atrial fibrillation treatments involving standalone surgical ablation and catheter ablation were discussed in data presentations at the American Heart Association annual meeting last week.
Safety Concerns Sink Medtronic A-Fib Catheter Ablation System At Panel
Risks associated with Medtronic’s Phased RF catheter ablation system for atrial fibrillation outweigh the benefits of the device, FDA’s Circulatory System Devices panel concluded in an 8-2 vote on Oct. 27.